Lysergic Acid Diethylamide (LSD) in Palliative Care (LPC)

This randomized, double-blind, active-placebo controlled trial (n=60) will evaluate the effects of LSD on psychosocial distress in patients suffering from an end-stage fatal disease with a life expectancy of 12 weeks to 2 years. Participants will be allocated in a 2:1 ratio to one of two intervention arms.

One arm will receive two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg), and the other arm will receive two low doses of LSD (25 µg and 25 µg) as an active-placebo control. The study is expected to begin in September 2023 and conclude in September 2027.

The main objective of the trial is to investigate whether LSD can alleviate depressive symptoms, anxiety, and improve the quality of life in terminally ill patients, based on evidence from pilot studies suggesting that serotonergic hallucinogens, including LSD and psilocybin, can have these effects.

Topic Palliative Care Depression Anxiety
Compound LSD
Country Switzerland
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.